Zypitamag (Pitavastatin Magnesium) Patent Expiration, LOE Window & CMS Spending

Zypitamag (Pitavastatin Magnesium) by Medicure International: FDA Orange Book core substance LOE 2031-01-19, 8 AB generics, $4.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMedicure International
FDA Application & PathwayN208379 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-01-19
Last Listed Patent or Exclusivity Date2031-01-19
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$4.0M
2024 Medicare Part D Spend$3.9M
2024 Medicaid Spend$52K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel